Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery



Status:Recruiting
Conditions:Liver Cancer, Liver Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 30
Updated:3/20/2019
Start Date:May 23, 2018
End Date:June 30, 2025

Use our guide to learn which trials are right for you!

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

This partially randomized phase II/III trial studies how well cisplatin and combination
chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer
after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil,
vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and
oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving combination
chemotherapy after surgery may kill more tumor cells.

PRIMARY OBJECTIVES:

I. To reduce therapy associated toxicity for patients with non-metastatic hepatoblastoma (HB)
and hepatocellular carcinoma (HCC) without adversely affecting long term outcomes.

II. To determine the event-free survival (EFS) in patients with HB whose tumor is completely
resected at diagnosis and either receive no adjuvant chemotherapy (completely resected well
differentiated fetal histology HB) or 2 cycles of standard dose cisplatin monotherapy
(completely resected non-well differentiated fetal histology HB ? 100 mg/m^2/cycle given 3
weeks apart). (Group A) III. To demonstrate that 4 to 6 cycles of interval compressed lower
dose cisplatin monotherapy (80 mg/m^2/cycle; 320 480 mg/m^2 total) is adequate for low risk
HB. (Group B) IV. In patients who are resected after 2 cycles of cisplatin monotherapy, to
compare EFS following a randomized comparison of 2 versus 4 post-operative cycles of
cisplatin monotherapy. (Group B) V. In patients whose tumors are deemed unresectable after 2
cycles of cisplatin monotherapy, to determine the proportion of tumors rendered completely
resectable by an additional 2 or 4 cycles of chemotherapy. (Group B) VI. To compare in a
randomized fashion, EFS in patients with intermediate risk HB treated with 6 cycles of
cisplatin/5-fluorouracil/vincristine/doxorubicin (C5VD) chemotherapy versus 6 cycles of
interval compressed cisplatin monotherapy (100 mg/m^2/dose). (Group C) VII. To determine the
EFS in patients with HCC whose tumor is completely resected at diagnosis who receive no
adjuvant chemotherapy (completely resected HCC arising in the context of underlying liver
disease) or 4 cycles of cisplatin/doxorubicin (PLADO) (completely resected de novo HCC).
(Group E) VIII. To improve the EFS of patients with high risk HB by treating them with
interval compressed cisplatin and doxorubicin based induction regimen followed by
response-adapted consolidation therapy. (Group D) IX. In patients whose metastatic disease
resolves with the administration of Societe Internationale d?Oncologie Pediatrique (SIOPEL) 4
Induction therapy, to determine if the promising pilot results observed in SIOPEL 4 can be
validated in a large international study. (Group D1) X. In patients whose metastatic disease
does not resolve with the administration of SIOPEL 4 Induction therapy, to determine in a
randomized comparison which post induction treatment (irinotecan and vincristine sulfate
[vincristine] alternating with carboplatin and doxorubicin or carboplatin and etoposide
alternating with carboplatin and doxorubicin) results in superior outcomes. (Group D Arm CE &
Arm VI) XI. In patients with unresectable/metastatic HCC at diagnosis, to determine whether
the addition of gemcitabine and oxaliplatin (GEMOX + sorafenib) to a cisplatin, doxorubicin
and sorafenib backbone improves chemotherapy response, resectability and survival. (Group F)

SECONDARY OBJECTIVES:

I. Molecular characterization of HB tumors to validate newly identified molecular and
immunohistochemical biomarkers correlating with known clinical prognostic factors and
outcome. (Group A-D) II. To determine whether the molecular profile of pediatric HCC overlaps
with HB or adult-type HCC while correlating biologic features with treatment response and
survival. (Group E and F) III. To define the prognostic relevance in HB of a ?small cell
undifferentiated? tumor component and percentage of tumor necrosis in post chemotherapy
specimens.

IV. To determine the concordance of Pretreatment Extent of Disease (PRETEXT) and
Post-treatment Extent of disease (POSTTEXT) based surgical guidelines and the surgical
intervention performed.

V. To determine which system (Children's Oncology Group [COG] PRETEXT, SIOPEL PRETEXT, or a
new hybrid definition of PRETEXT) of the annotation factors for V, P, E, F and R provides the
best prognostic information for determining response to chemotherapy, guiding risk based
therapy, predicting surgical resectability, and EFS.

VI. To determine the concordance between institutional and expert panel review assessment of
PRETEXT and POSTTEXT stage in an international cooperative group setting.

VII. To assess clinical characteristics, basic chemotherapy and surgical treatment details,
biological characteristics at baseline and recurrence (when available) and outcome of
patients with refractory or relapsed hepatoblastoma after initial treatment.

VIII. To identify novel biomarkers of renal toxicity (urine NGAL, cystatin C and Kim1) from
cisplatin therapy when given according to the regimens used on this study, and to correlate
such biomarkers with pharmacogenomics, other associated toxicities, and outcomes.

TERTIARY OBJECTIVES:

I. To determine if the Childhood Hepatic tumor International Consortium (CHIC) hepatoblastoma
risk stratification analysis of very low risk (Group A), low risk (Group B), intermediate
risk (Group C) and high risk (Group D) groups stratifies patients allowing appropriate
utilization of varying intensity chemotherapy regimens and surgical resection strategies.

II. To define the prognostic relevance of a positive microscopic margin in Group A-D resected
HB specimens.

III. To define the frequency of histologically detectable multifocal lesions in liver
explants and resected specimens in which multifocal disease was detected at diagnosis and
disappeared on cross sectional imaging following treatment with chemotherapy.

IV. To determine the prognostic impact on EFS and overall survival (OS) of biopsy technique
in liver tumors unresectable at diagnosis.

V. To determine the frequency of intraoperative complications from surgery for local control
(conventional resection or liver transplantation) and its impact on EFS.

VI. To determine the 3-year EFS and OS of HB patients who undergo liver transplantation
versus (vs) extreme resection in Group C and D patients.

VII. To determine the 3-year EFS and OS of Group D patients who undergo pulmonary
metastatectomy.

VIII. To determine the 3-year EFS and OS of patients who undergo liver transplantation for
HCC.

IX. To determine the frequency of relapse in non-metastatic HCC in children treated by liver
transplantation versus conventional resection.

X. To assess the pharmacogenomics (PG) related to cisplatin therapy in pediatric and
adolescent liver tumor patients and correlate PG with Boston Grading Scale for ototoxicity.

OUTLINE:

GROUP A (VERY LOW RISK HB): Patients are assigned to 1 of 2 groups.

GROUP A1 (WELL-DIFFERENTIATED FETAL [WDF]): Patients undergo observation.

GROUP A2 (NON-WDF): Patients receive cisplatin (CDDP) intravenously (IV) over 6 hours on day
1 following surgery. Treatment repeats every 21 days for up to 2 courses in the absence of
disease progression or unacceptable toxicity.

GROUP B (LOW RISK HB): Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats
every 14 days for up to 2 courses in the absence of disease progression or unacceptable
toxicity. Patients are then assigned to 1 of 2 groups

GROUP B1 (RESECTABLE): Patients undergo surgery, then are randomized to 1 of 2 arms.

GROUP B1 ARM 4-CDDP: Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats
every 14 days for up to 2 courses in the absence of disease progression or unacceptable
toxicity.

GROUP B1 ARM 6-CDDP: Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats
every 14 days for up to 4 courses in the absence of disease progression or unacceptable
toxicity.

GROUP B2 (UNRESECTABLE): Patients receive cisplatin IV over 6 hours on day 1. Treatment
repeats every 14 days for up to 2 courses. Patients with resectable tumors undergo surgery,
then all patients continue with 2 additional courses of cisplatin.

GROUP C (INTERMEDIATE RISK HB): Patients are randomized to 1 of 2 arms.

GROUP C ARM CDDP: Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats
every 14 days for up to 6 courses in the absence of disease progression or unacceptable
toxicity. Patients undergo surgery after course 2.

GROUP C ARM C5VD: Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over
1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV
over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity. Patients undergo surgery after
course 2.

GROUP D (HIGH RISK HB): SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on
days 1, 8, and 15 (for courses 1 and 2) and days 1 and 8 (for course 3) and doxorubicin IV
over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 courses in the
absence of disease progression or unacceptable toxicity. Patients are then assigned to 1 of 2
arms.

GROUP D1: CONSOLIDATION THERAPY: Patients with lung complete remission (either with
chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV
over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 courses in the
absence of disease progression or unacceptable toxicity.

GROUP D2: Patients with residual metastatic disease are randomized to 1of 2 arms.

GROUP D2 ARM CE: Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV
over 1-15 minutes on days 1 and 2 during courses 1, 3 and 5, and etoposide IV over 2 hours on
day 1 and 2 of courses 2, 4 and 6. Treatments repeat every 21 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity.

GROUP D2 ARM VI: Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin
IV over 1-15 minutes on days 1 and 2 during courses 1, 3 and 5. Patients also receive
vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes once
daily (QD) on days 1 to 5 of courses 2, 4 and 6. Treatments repeat every 21 days for up to 6
courses in the absence of disease progression or unacceptable toxicity.

GROUP E (RESECTED HCC): Patients are assigned to 1 of 2 groups.

GROUP E1: Patients with HCC secondary to disease undergo observation only.

GROUP E2 (PLADO): Patients with de novo HCC receive cisplatin IV over 6 hours on day 1 and
doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every
21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

GROUP F (UNRESECTED AND/OR METASTATIC HCC): Patients are randomized to 1 of 2 arms.

GROUP F ARM 1 (PLADO): Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV
over 1-15 minutes on days 1 and 2 and sorafenib orally (PO) twice daily (BID) on days 3-21.
Treatments repeat every 21 days for up to 3 courses in the absence of disease progression or
unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an
additional 3 courses of the treatment.

GROUP F ARM 2 (P/GEMOX): Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV
over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of courses 1 and 3.
Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on
day 1 and sorafenib PO on days 1-14 of courses 2 and 4. Patients may undergo surgery, if
tumors are resectable, or receive an additional 4 courses of the treatment.

After completion of study treatment, patients are followed up for a minimum of 2 years.

Inclusion Criteria:

- Patients must have a performance status corresponding to Eastern Cooperative Oncology
Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and
Lansky for patients =< 16 years of age; patients who are unable to walk because of
paralysis, but who are up in a wheelchair, will be considered ambulatory for the
purpose of assessing the performance score

- Patients must be newly diagnosed with histologically-proven primary pediatric hepatic
malignancies including hepatoblastoma or hepatocellular carcinoma, except as noted
below; note that rapid central pathology review is required in some cases; please
note: all patients with histology as assessed by the institutional pathologist
consistent with pure small cell undifferentiated (SCU) HB will be required to have
testing for INI1/SMARCB1 by immunohistochemistry (IHC) according to the practices at
the institution

- Patients with histology consistent with pure SCU must have positive INI1/SMARCB1
staining

- In emergency situations when a patient meets all other eligibility criteria and has
had baseline required observations, but is too ill to undergo a biopsy safely, the
patient may be enrolled without a biopsy

- Clinical situations in which emergent treatment may be indicated include, but are
not limited to, the following circumstances:

- Anatomic or mechanical compromise of critical organ function by tumor (e.g.,
respiratory distress/failure, abdominal compartment syndrome, urinary
obstruction, etc.)

- Uncorrectable coagulopathy

- For a patient to maintain eligibility for AHEP1531 when emergent treatment is
given, the following must occur:

- The patient must have a clinical diagnosis of hepatoblastoma, including an
elevated alphafetoprotein (AFP), and must meet all AHEP1531 eligibility
criteria at the time of emergent treatment

- Patient must be enrolled on AHEP1531 prior to initiating protocol therapy; a
patient will be ineligible if any chemotherapy is administered prior to
AHEP1531 enrollment

- Note: If the patient receives AHEP1531 chemotherapy emergently PRIOR to
undergoing a diagnostic biopsy, pathologic review of material obtained in the
future during either biopsy or surgical resection must either confirm the
diagnosis of hepatoblastoma or not reveal another pathological diagnosis to be
included in the analysis of the study aims

- Patients may have had surgical resection of the hepatic malignancy prior to
enrollment; all other anti-cancer therapy for the current liver lesion is prohibited

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or

- A serum creatinine based on age/gender as follows:

- Age: maximum serum creatinine (mg/dL)

- 1 month to < 6 months: 0.4 (male and female)

- 6 months to < 1 year: 0.5 (male and female)

- 1 to < 2 years: 06 (male and female)

- 2 to < 6 years: 0.8 (male and female)

- 6 to < 10 years: 1 (male and female)

- 10 to < 13 years: 1.2 (male and female)

- 13 to < 16 years: 1.5 (male), 1.4 (female)

- >= 16 years: 1.7 (male), 1.4 (female)

- Total bilirubin =< 5 x upper limit of normal (ULN) for age

- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
< 10x upper limit of normal (ULN) for age

- Shortening fraction of >= 27% by echocardiogram (for patients on
doxorubicin-containing regimens [Groups C, D, E, and F]), or

- Ejection fraction of >= 50% by radionuclide angiogram (for patients on
doxorubicin-containing regimens (Groups C, D, E, and F)

- Normal pulmonary function tests (including diffusion capacity of the lung for carbon
monoxide [DLCO]) if there is clinical indication for determination (e.g. dyspnea at
rest, known requirement for supplemental oxygen); for patients who do not have
respiratory symptoms or requirement for supplemental oxygen, pulmonary function tests
(PFTs) are NOT required

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met

Exclusion Criteria:

- Prior chemotherapy or tumor directed therapy (i.e. radiation therapy, biologic agents,
local therapy (embolization, radiofrequency ablation, and laser); therefore, patients
with a pre-disposition syndrome who have a prior malignancy are not eligible

- Patients who are currently receiving another investigational drug

- Patients who are currently receiving other anticancer agents

- Patients with uncontrolled infection

- Patients who previously received a solid organ transplant

- This criteria apply ONLY to patients who will receive chemotherapy (all groups other
than Group E1):

- Female patients who are pregnant; a pregnancy test is required for female
patients of childbearing potential

- Lactating females who plan to breastfeed their infants

- Sexually active patients of reproductive potential who have not agreed to use an
effective contraceptive method for the duration of their study participation

- Note for Group F: patients of childbearing potential should use effective
birth control during treatment with sorafenib and for at least 2 weeks after
stopping treatment
We found this trial at
122
sites
Hershey, Pennsylvania 17033
Principal Investigator: Lisa M. McGregor
?
mi
from
Hershey, PA
Click here to add this to my saved trials
4900 Mueller Boulevard
Austin, Texas 78723
(512) 324-0000
Principal Investigator: Amy C. Fowler
Dell Children's Medical Center of Central Texas Welcome to Dell Children
?
mi
from
Austin, TX
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Matthew A. Kutny
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Clare J. Twist
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Jessica L. Heath
?
mi
from
Burlington, VT
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: James I. Geller
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
(216) 844-1000
Principal Investigator: John J. Letterio
Phone: 216-844-5437
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Mark A. Ranalli
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
7777 Forest Ln # C840
Dallas, Texas 75230
(972) 566-7000
Principal Investigator: Stanton C. Goldman
Phone: 972-566-5588
Medical City Dallas Hospital If you have concerns for your health, that of a family...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1200 Pleasant Street
Des Moines, Iowa 50309
(515) 241-KIDS
Principal Investigator: Samantha L. Mallory
Blank Children's Hospital Blank Children's Hospital is completely dedicated to meeting the unique health care...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Marshall A. Schorin
Phone: 703-208-6650
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Michael S. Isakoff
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Anderson (Andy) B. Collier
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Leo Mascarenhas
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Wayne L. Furman
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
(757) 668-7000
Principal Investigator: Eric J. Lowe
Children's Hospital of The King's Daughters Children
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
747 52nd St
Oakland, California 94609
(510) 428-3000
Principal Investigator: Carla B. Golden
Children's Hospital and Research Center Oakland For nearly 100 years, Children's Hospital & Research Center...
?
mi
from
Oakland, CA
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Principal Investigator: Elyssa M. Rubin
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
530 Northeast Glen Oak Avenue
Peoria, Illinois 61603
(309) 624-4945
Principal Investigator: Jaime M. Libes
Phone: 888-226-4343
Saint Jude Midwest Affiliate The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic was...
?
mi
from
Peoria, IL
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Elizabeth Fox
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Louis B. Rapkin
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Linda C. Stork
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Frances Austin
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Anne-Marie R. Langevin
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
1600 Rockland Road
Wilmington, Delaware 19803
(302) 651-4200
Principal Investigator: Ramamoorthy Nagasubramanian
Phone: 302-651-6884
Alfred I. duPont Hospital for Children Nemours began more than 70 years ago with the...
?
mi
from
Wilmington, DE
Click here to add this to my saved trials
Akron, Ohio 44308
Principal Investigator: Steven J. Kuerbitz
?
mi
from
Akron, OH
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Brenda J. Wittman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Laura Sedig
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Douglas J. Scothorn
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Kathryn S. Sutton
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Brian S. Greffe
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Jason M. Fixler
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Alan D. Friedman
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Nadine P. SantaCruz
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Kenneth Lieuw
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Eugenia Chang
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Allison F. O'Neill
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02111
Principal Investigator: Michael J. Kelly
Phone: 617-636-5535
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Lisa Gennarini
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Stuart H. Gold
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Amy L. Walz
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Ami V. Desai
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Rabi Hanna
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbia, Missouri 65201
Principal Investigator: Barbara A. Gruner
?
mi
from
Columbia, MO
Click here to add this to my saved trials
5 Richland Medical Park Dr
Columbia, South Carolina 29203
(803) 434-7000
Principal Investigator: Stuart L. Cramer
Phone: 803-434-3680
Palmetto Health Richland Palmetto Health Richland, originally founded in 1892 as Columbia Hospital, has a...
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Jonathan E. Wickiser
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jennifer J. Clark
?
mi
from
Denver, CO
Click here to add this to my saved trials
9333 Imperial Highway
Downey, California 90242
Principal Investigator: Robert M. Cooper
Phone: 510-891-3400
?
mi
from
Downey, CA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Lars M. Wagner
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fort Myers, Florida 33908
Principal Investigator: Emad K. Salman
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
(682) 885-4000
Principal Investigator: Lauren J. Akers
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: William B. Slayton
Phone: 352-273-8010
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Katharine Offer
Phone: 201-996-2879
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hollywood, Florida 33021
Principal Investigator: Iftikhar Hanif
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
(808) 983-6000
Principal Investigator: Wade T. Kyono
Phone: 808-983-6090
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Valeria Smith
Phone: 713-798-1354
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Najat C. Daw
Phone: 877-312-3961
?
mi
from
Houston, TX
Click here to add this to my saved trials
Hunter Regional Mail Centre, New South Wales
Principal Investigator: Draga Barbaric
?
mi
from
Hunter Regional Mail Centre,
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: Kamnesh R. Pradhan
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Mariko Sato
Phone: 800-237-1225
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Ramamoorthy Nagasubramanian
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Missouri 64108
Principal Investigator: Keith J. August
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
2018 W Clinch Ave
Knoxville, Tennessee 37916
(865) 541-8000
Principal Investigator: Ray C. Pais
Phone: 865-541-8266
East Tennessee Children's Hospital East Tennessee Children's Hospital is a not-for-profit, private, independent pediatric medical...
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Las Vegas, Nevada 89135
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89144
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Julie Kim
Phone: 800-639-6918
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Lexington, Kentucky
Principal Investigator: Vlad C. Radulescu
Phone: 859-257-3379
?
mi
from
Lexington, KY
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: David L. Becton
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Noah C. Federman
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Ashok B. Raj
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Madera, California 93638
Principal Investigator: Vonda L. Crouse
?
mi
from
Madera, CA
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Kenneth B. De Santes
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
Principal Investigator: Michelle A. Manalang
Phone: 800-782-8581
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
Mesa, Arizona 85202
Principal Investigator: Hardeo K. Panchoosingh
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Julio C. Barredo
Phone: 305-243-2647
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33155
Principal Investigator: Enrique A. Escalon
?
mi
from
Miami, FL
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Emily G. Greengard
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
2525 Chicago Ave
Minneapolis, Minnesota 55404
(612) 813-6000
Principal Investigator: Michael K. Richards
Children's Hospitals and Clinics of Minnesota - Minneapolis Children's Hospitals and Clinics of Minnesota is...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Morgantown, West Virginia 26505
Principal Investigator: Stephan R. Paul
Phone: 304-293-7374
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Haydar A. Frangoul
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Scott C. Borinstein
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Richard A. Drachtman
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Nina S. Kadan-Lottick
Phone: 203-785-5702
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Craig Lotterman
Phone: 504-703-8712
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New Orleans, Louisiana 70118
Principal Investigator: Lolie C. Yu
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Pillai Pallavi Madhusoodhan
Phone: 212-824-7309
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Alice Lee
Phone: 212-305-6361
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Michael V. Ortiz
Phone: 212-639-7592
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oakland, California 94611
Principal Investigator: Laura A. Campbell
Phone: 877-642-4691
?
mi
from
Oakland, CA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Rene Y. McNall-Knapp
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Don E. Eslin
Phone: 321-843-2584
?
mi
from
Orlando, FL
Click here to add this to my saved trials
13535 Nemours Parkway
Orlando, Florida 32827
(407) 567-4000
Principal Investigator: Ramamoorthy Nagasubramanian
Nemours Children's Hospital Nemours Children's Hospital in Orlando brings pediatric specialty care never before offered...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
725 Welch Rd
Palo Alto, California 94304
(650) 497-8000
Principal Investigator: Sheri L. Spunt
Lucile Packard Children's Hospital Stanford University Stanford Children's Health is the only network in the...
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
3601 A St
Philadelphia, Pennsylvania 19134
(215) 427-5000
Principal Investigator: Gregory E. Halligan
Saint Christopher's Hospital for Children St. Christopher's Hospital for Children offers a wide range of...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Principal Investigator: Jessica Boklan
Phone: 602-546-0920
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
2801 N Gantenbein Ave
Portland, Oregon 97227
(503) 276-6500
Principal Investigator: Janice F. Olson
Legacy Emanuel Children's Hospital For generations our children's hospital has provided outstanding care for kids...
?
mi
from
Portland, OR
Click here to add this to my saved trials